1773 PREDICTION OF RECURRENCE AND PROGRESSION IN THE CONTEXT OF THE CHARLSON COMORBIDITY INDEX IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER

Serena Yang,Guoqing Chen,Guilherme Godoy,Seth Lerner

DOI: https://doi.org/10.1016/j.juro.2013.02.2863

2013-01-01

Abstract:You have accessJournal of UrologyBladder Cancer: Superficial (II)1 Apr 20131773 PREDICTION OF RECURRENCE AND PROGRESSION IN THE CONTEXT OF THE CHARLSON COMORBIDITY INDEX IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER Serena Yang, Guoqing Chen, Guilherme Godoy, and Seth Lerner Serena YangSerena Yang Houston, TX More articles by this author , Guoqing ChenGuoqing Chen Houston, TX More articles by this author , Guilherme GodoyGuilherme Godoy Houston, TX More articles by this author , and Seth LernerSeth Lerner Houston, TX More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2863AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Non-muscle invasive bladder cancer (NMIBC) has a high-rate of disease recurrence and progression in high-grade disease. We hypothesized that the Charlson Comorbidity Index (CCI) is an independent predictor of disease-specific prognosis. METHODS We conducted a single institution retrospective review of NMIBC cases treated between 12/1985 and 06/2011. Both raw and age-adjusted CCI, demographics, use of intravesical chemotherapy and immunotherapy, clinical stage and grade, and time to recurrence and progression were recorded. Patients were divided into groups 1, 2, or 3, according to a raw CCI of 0-1, 2-3, and 4+, respectively. RESULTS We identified 333 patients who met the IRB approved study entry criteria, 274 (82.3%) males and 59 (17.7%) females. Median age at NMIBC diagnosis was 67 years. Initial disease stage distribution of Ta±Tis, T1±Tis, Tis alone, and unknown were 136 (40.8%), 136 (40.8%), 43 (12.9%), and 18 (5.4%), respectively. Using the EAU risk stratification criteria 194 (58.3%), 136 (40.8%) and 3 (1.0%) patients were high, low/intermediate, and unknown risk. We identified 219 (65.8%) patients with a positive smoking history. Of those, 170 had pack-years recorded, with a mean value of 39.3 (0.5-200, SD 29.8). Also, 183 (54.9%) patients underwent some form of intravesical chemotherapy and/or immunotherapy as part of their NMIBC management. Recorded deaths occurred in 49(14.7%) patients. Recurrence and progression data were available for 317 and 303 patients, respectively. In groups 1, 2, and 3, disease recurrence was seen in 140/236 (59.3%), 49/67 (73.1%), and 10/14 (71.4%) patients, and disease progression in 66/226 (29.2%), 29/64 (45.3%), and 5/13 (38.5%) patients, respectively. Median time to recurrence in groups 1, 2, and 3 was 22.5, 13.8, and 4.9 months, and median time to progression was 275.4, 38.8, and 59.4 months, respectively; all pairwise comparisons had p<0.05. CCI was an independent predictor for recurrence in multivariable models controlling for stage, grade, age, race, ethnicity and smoking history. CCI was not significantly associated with progression when controlled for smoking history or age. CONCLUSIONS Patients with NMIBC and a high CCI are at higher risk for recurrence and progression. Comorbidites should be considered in risk adjusted surveillance protocols and included as a covariate in clinical trial design of NMIBC treatment. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e729 Peer Review Report Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Serena Yang Houston, TX More articles by this author Guoqing Chen Houston, TX More articles by this author Guilherme Godoy Houston, TX More articles by this author Seth Lerner Houston, TX More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...